hidradenoma papilliferum
Recently Published Documents


TOTAL DOCUMENTS

97
(FIVE YEARS 17)

H-INDEX

18
(FIVE YEARS 1)

2021 ◽  
pp. e2021070
Author(s):  
Andrija Jovic ◽  
Danijela Popovic ◽  
Sladjana Cekic ◽  
Natasa Vidovic ◽  
Nikola Zivkovic ◽  
...  

2021 ◽  
pp. 100886
Author(s):  
Monica FG McGauran ◽  
Tom Manolitsas ◽  
Bassam Tawfik ◽  
Dhaval Joshi ◽  
Julie M Lamont

2021 ◽  
Vol 84 (2) ◽  
Author(s):  
Ayhan Atıgan ◽  
Derya Kılıç ◽  
Yeliz Arman Karakaya ◽  
Ömer Tolga Güler

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Ozer Birge ◽  
Mehmet Sait Bakır ◽  
Ceyda Karadag ◽  
Zivar Eldarova ◽  
Tayup Simsek

Abstract Background Hidradenoma papilliferum is a rare benign neoplasm arising from apocrine glands. It occurs commonly on the anogenital region of middle-aged women. It usually presents as a slow growing, solitary asymptomatic, skin colored or red nodule less than 1 cm in diameter. Case presentation The case is a 38-year-old, white woman who presented with a painful nodule occurring within a month in the himenal region of the posterior vaginal introitus. The nodule was excisied and the histology revealed a hidradenoma papilliferum. The diagnosis and treatment of hidradenoma papilliferum is possible with surgical removal and histopathological evaluation of nodules. Conclusion When an adult woman presents with a noduler lesion in the anogenital area, sexually transmitted diseases and other benign and malignant vulvar lesions, as well as malignant transformation is very rare but,should be kept in mind; however because it has been reported and long-term clinical follow-up is suggested


2020 ◽  
Vol 45 (8) ◽  
pp. 1035-1039
Author(s):  
G. Tosti ◽  
C. Salvini ◽  
A. Barisani ◽  
R. Grazi ◽  
S. Pirola ◽  
...  

2020 ◽  
Vol 5 (1) ◽  
pp. 10-11
Author(s):  
Kaoutar Laamari ◽  
◽  
Hanane Baybay ◽  
Samia Mrabat ◽  
Zakia Douhi ◽  
...  

2020 ◽  
Vol 28 (7) ◽  
pp. 711-720
Author(s):  
Jun Zhou ◽  
Haimin Xu ◽  
Hong Zeng ◽  
Hongjun Ma ◽  
Jingjing Yu ◽  
...  

Background. The expression of terminal deoxynucleotidyl transferase (TdT) in myoepithelial cells (MECs) within the breast was recently incidentally observed in our routine practice. This study aimed to elucidate the expression of TdT in MECs. Methods. TdT immunostaining was performed on 180 mammary, 89 cutaneous, and 94 salivary tissues or lesions. Other myoepithelial markers, including P63, calponin, and SMA as well as double staining for TdT and calponin, were also evaluated in some cases. Selected lesions with basal or myoid differentiation were also included in the investigation. Results. MECs were positive for TdT in mammary lesions that contained MECs (132/135) but negative when they did not contain MECs (45/45). MECs in sweat glands (24/30) and their neoplastic counterparts, including those in hidradenoma papilliferum (2/9), spiradenoma (6/6), and cutaneous mixed tumor (9/9), showed weak to moderate TdT positivity. MECs were variably immunolabeled for TdT in salivary or salivary gland–type tumors with myoepithelial differentiation (pleomorphic adenoma, 24/25; basal cell adenoma, 6/7; adenoid cystic carcinoma, 7/7; Warthin tumor, 0/6; mucoepidermoid carcinoma, 0/8; acinic cell carcinoma, 0/4), but MECs in normal salivary gland barely stained for TdT (30/32). Conclusions. Our findings indicate that TdT may be eligible as an additional auxiliary immunohistochemical marker as P63, but not a surrogate, to identify the MECs in the breast with limited cross-reactivity, particularly in lesions with a prominent proportion of MECs. Positivity for TdT, along with other relevant markers, in a subset of sweat gland lesions and salivary tumors may contribute to their diagnosis.


2020 ◽  
Vol 65 (2) ◽  
pp. 151
Author(s):  
WilliamClark Lambert ◽  
Shreya Patel ◽  
Sara Behbanani ◽  
JoseD Espinal-Mariotte ◽  
Patricia Lee

Sign in / Sign up

Export Citation Format

Share Document